3Chang JW, Jeon HB, Lee JH, et al. Augmented expression ofperoxiredoxin I in lung cancer. Biochem Biophys Res Commun, 2001,289(2):507-512.
4Ying W, Zhang K, Qian X,et al. Proteome analysis on an earlytransformed human bronchial epithelial cell line, BEP2D, afteralpha-particle irradiation. Proteomics, 2003, 3(1):64-72.
5Wang Cl, Chien KY, Wang CL, et al. Quantitative proteomics revealsregulation of karyopherin subunit alpha-2 (KPNA2) and its potentialnovel cargo proteins in nonsmall cell lung cancer. Mol CellProteomics, 2012, 11(11):1105-1122.
9Planque C, Kulasingam V,Smith CR, et al. Identification of fivecandidate lung cancer biomarkers by proteomics analysis ofconditioned media of four lung cancer cell lines. Mol Cell Proteomics,2009,8(12):2746-2758.
10Zeng GQ, Zhang PF, Deng X,et al. Identification of candidatebiomarkers for early detection of human lung squamous cell cancer byquantitative proteomics. Mol Cell Proteomics, 2012, 11(6):M111.013946.
8Wang CC Tsou CL.-[J].Acta Biochinica et Biophysica Sinica（生物化学与生物物理学报：英文版）,1998,30:533-539.
9Chen P Xie JY 等.-[J].Acta Biochinica et Biophysica Sinica（生物化学与生物物理学报：英文版）,2000,32:387-391.
10BHARTI A, MAP C, SALGIA R. Biomarker discovery in lung cancer-promises and challenges of clinical proteomics [ J ]. Mass Spectrom Rev, 2007, 26(3):451-466.
1Muller PA,Vousden K H.Mutant p53 in cancer:new functions and therapeutic opportunities[J]. Cancer Cell, 2014,25 (3) : 304--317.
2Kandoth C, McLellan MD, Vandin F, et aL Mutational landscape and significance across 12 major cancer types[J]. Nature,2013,502(7471) :333--339.
3Choudhury S, Kolukula VK, Preet A, et al. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? [J]. Cell Cycle,2013,12(7) : 1022-- 1029.
4Chen S, Wang DL, Liu Y, et al. RAD6 regulates the dosage of p53 by a combination of transcriptional and posttranscriptional mechanisms[J]. Mol Cell Biol, 2012,32 (2) :576--587.
